Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “RET Fusion”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 19 of 0 results

Early research (Phase 1)Study completedNCT03784378
What this trial is testing

Continued Access to RXDX-105

Who this might be right for
Non Small Cell Lung CancerOvarian CancerRET Gene Mutation+1 more
Memorial Sloan Kettering Cancer Center 3
Large-scale testing (Phase 3)Ended earlyNCT04222972
What this trial is testing

Pralsetinib Versus Standard of Care for First-Line Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC)

Who this might be right for
RET-fusion Non Small Cell Lung CancerLung NeoplasmCarcinoma, Non-Small-Cell Lung+14 more
Hoffmann-La Roche 223
Post-approval studies (Phase 4)Looking for participantsNCT07704658
What this trial is testing

Pralsetinib DDI Study in Patients With Advanced or Metastatic Solid Tumors

Who this might be right for
NSCLC (Non-small Cell Lung Cancer)Thyroid CancerSolid Tumor Malignancies+1 more
Rigel Pharmaceuticals 12
Testing effectiveness (Phase 2)Looking for participantsNCT05668962
What this trial is testing

Restor. I-131 Upt. + Selpercatinib in RET F-P RAI-R TC

Who this might be right for
Thyroid CancerThyroid CarcinomaMetastatic Thyroid Cancer+3 more
Massachusetts General Hospital 30
Large-scale testing (Phase 3)Active Not RecruitingNCT06031558
What this trial is testing

Phase III Study of SY-5007, a RET Inhibitor, in Patients With Locally Advanced or Metastatic RET Fusion-positive NSCLC

Who this might be right for
Non-Small Cell Lung Cancer
Shouyao Holdings (Beijing) Co. LTD 120
Testing effectiveness (Phase 2)Active Not RecruitingNCT04268550
What this trial is testing

Targeted Treatment for RET Fusion-Positive Advanced Non-Small Cell Lung Cancer (A LUNG-MAP Treatment Trial)

Who this might be right for
Recurrent Lung Non-Small Cell CarcinomaStage IV Lung Cancer AJCC v8Stage IVA Lung Cancer AJCC v8+1 more
SWOG Cancer Research Network 124
Large-scale testing (Phase 3)Looking for participantsNCT07809256
What this trial is testing

A Prospective, Single-center, Non-randomized, Interventional Study on the Effectiveness and Safety of Combined Immunotargeted Therapy in Patients With Metastatic Non-small Cell Cancer With a RET Gene Translocation

Who this might be right for
NSCLC (Non-small Cell Lung Cancer)R
EuroCityClinic LLC 15
Testing effectiveness (Phase 2)UnknownNCT05117658
What this trial is testing

Study of HA121-28 in Patients With Non-Small Cell Lung Cancer

Who this might be right for
NSCLC
CSPC ZhongQi Pharmaceutical Technology Co., Ltd. 83
Not applicableNot Yet RecruitingNCT07042984
What this trial is testing

RET-US Study - Ultrasound-Based Prediction of RET Alterations and Lateral-Neck Metastasis in Thyroid Cancer

Who this might be right for
Papillary Thyroid CarcinomaThyroid NeoplasmsRET Proto-Oncogene Mutation+1 more
Fujian Medical University 800
Testing effectiveness (Phase 2)Looking for participantsNCT01639508
What this trial is testing

Cabozantinib in Patients With RET Fusion-Positive Advanced Non-Small Cell Lung Cancer and Those With Other Genotypes: ROS1 or NTRK Fusions or Increased MET or AXL Activity

Who this might be right for
Non-Small Cell Lung Cancer
Memorial Sloan Kettering Cancer Center 86
Testing effectiveness (Phase 2)Looking for participantsNCT06147570
What this trial is testing

HS-10365 in Patients With Advanced or Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer

Who this might be right for
Nonsmall Cell Lung Cancer
Jiangsu Hansoh Pharmaceutical Co., Ltd. 62
Not applicableStudy completedNCT02450123
What this trial is testing

Single-arm Study to Evaluate the Safety and Efficacy of Sunitinib, in Subjects With RET Fusion Positive or FGFR2 Amplification, Refractory Solid Tumors

Who this might be right for
Refractory Solid Tumors
Samsung Medical Center 1
Not applicableNot Yet RecruitingNCT07418879
What this trial is testing

A Real-world Study of Pralsetinib Combined With Leucogen in the Treatment of RET Fusion-positive NSCLC

Who this might be right for
Non-small Cell Lung CancerRET FusionPralsetinib
Fudan University 25
Testing effectiveness (Phase 2)UnknownNCT05278364
What this trial is testing

Phase I/II Study of SY-5007, a RET Inhibitor, in Patients With RET-altered Advanced Solid Tumor

Who this might be right for
Non-Small Cell Lung CancerMedullary Thyroid CancerSolid Tumor
Shouyao Holdings (Beijing) Co. LTD 184
Testing effectiveness (Phase 2)Ended earlyNCT04161391
What this trial is testing

Study of TPX-0046, A RET/SRC Inhibitor in Adult Subjects With Advanced Solid Tumors Harboring RET Fusions or Mutations

Who this might be right for
Non Small Cell Lung CancerMedullary Thyroid CancerRET Gene Mutation+2 more
Turning Point Therapeutics, Inc. 41
Post-approval studies (Phase 4)Not Yet RecruitingNCT07010393
What this trial is testing

Genotype-Driven Neoadjuvant Therapy for Locally Advanced Thyroid Cancer: A Real-World Cohort Study

Who this might be right for
Thyroid Neoplasms
Fujian Medical University 335
Large-scale testing (Phase 3)Active Not RecruitingNCT04819100
What this trial is testing

Selpercatinib After Surgery or Radiation in Participants With Non-Small Cell Lung Cancer (NSCLC)

Who this might be right for
Carcinoma, Non-Small-Cell Lung
Eli Lilly and Company 152
Not applicableUnknownNCT04322591
What this trial is testing

Chemotherapy or Chemotherapy Plus PD-1 Antibody in RET Fusion Positive Advanced NSCLC Patitnts: the POSEIDON Trial

Who this might be right for
Non-small Cell Lung Cancer
Hunan Province Tumor Hospital 70
Testing effectiveness (Phase 2)Active Not RecruitingNCT05265091
What this trial is testing

KL590586 in Patients With Advanced Solid Tumors

Who this might be right for
Advanced Solid Tumor
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. 414